Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study.
Authors
Coutinho, Lucia HChang, James
Brereton, M L
Morgenstern, Godfrey R
Scarffe, J Howard
Harrison, Christine J
Yin, J A
Darbyshire, P J
Burdach, S
Dexter, T Michael
Testa, Nydia G
Affiliation
CRC Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.Issue Date
1997-05
Metadata
Show full item recordAbstract
Incubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rationale for using marrow cells from 10-day-old LTC to autograft nine chronic phase CML patients, ineligible for HLA-matched sibling donor transplant, and who were selected on the basis of a pre-transplant screening LTC test. Of the transplanted patients three died; two of graft failure and one of therapy-related toxicity with 97% Ph- cells 16 months following the autograft. The reconstituting haemopoietic cells in the seven engrafted patients were 100% Ph- in four, > or = 90% Ph- in two and 71% Ph- in the seventh, with a duration of complete cytogenetic response of 6-12 months. Three patients reverted to chronic phase and 100% Ph+ haemopoiesis 27-36 months post-autograft. The other three patients remain in continuous haematological remission with 22% Ph- cells in one and complete cytogenetic remission in the other two 3-4 years post-autograft. IFN therapy was generally introduced on the first evidence of recurrence of Ph+ cells or of cytogenetic deterioration. Further strategies to modulate immune surveillance in vivo may improve the outcome of cultured marrow autografts which give an initial and rather prolonged bias towards Ph- haemopoiesis.Citation
Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study. 1997, 19 (10):969-76 Bone Marrow Transplant.Journal
Bone Marrow TransplantationDOI
10.1038/sj.bmt.1700777PubMed ID
9169640Type
ArticleLanguage
enISSN
0268-3369ae974a485f413a2113503eed53cd6c53
10.1038/sj.bmt.1700777
Scopus Count
Related articles
- Autografting in chronic myeloid leukemia with cultured marrow: update of the Vancouver Study.
- Authors: Barnett MJ, Eaves CJ, Phillips GL, Hogge DE, Klingemann HG, Lansdorp PM, Nantel SH, Reece DE, Shepherd JD, Sutherland HJ
- Issue date: 1993 Oct
- Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
- Authors: Carlo-Stella C, Regazzi E, Andrizzi C, Savoldo B, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G
- Issue date: 1997 May-Jun
- High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
- Authors: Carella AM, Chimirri F, Podestà M, Pitto A, Piaggio G, Dejana A, Lerma E, Pollicardo N, Vassallo F, Soracco M, Benvenuto F, Valbonesi M, Carlier P, Vimercati R, Prencipe E, Gatti AM, Ferrara RA, Incagliato M, Florio G, Frassoni F
- Issue date: 1996 Feb
- Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
- Authors: Carlo-Stella C, Mangoni L, Almici C, Caramatti C, Cottafavi L, Dotti GP, Rizzoli V
- Issue date: 1994 Sep
- Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow.
- Authors: Rizzoli V, Mangoni L, Almici C, Caramatti C, Dotti GP, Carlo-Stella C
- Issue date: 1993 Oct